Tonix Pharmaceuticals Holding Corp. reported financial results for the fourth quarter and full year ended December 31, 2025, highlighting the successful U.S. launch of TONMYA, the first new medicine approved for fibromyalgia in more than 15 years. The U.S. Food and Drug Administration approved the product in August 2025, and it became commercially available by prescription on November 17, 2025. Early launch metrics indicate growing prescriber uptake, with more than 1,500 healthcare providers prescribing the therapy and approximately 2,500 patients initiating treatment.
The company's financial position remains strong, ending the year with approximately $207.6 million in cash and cash equivalents, which management states will support operations into the first quarter of 2027. This financial stability provides Tonix with the resources to continue commercializing TONMYA while advancing its broader pipeline of central nervous system and immunology treatments.
Beyond the TONMYA launch, Tonix advanced several pipeline programs during 2025. The company in-licensed TNX-4800 for the seasonal prevention of Lyme disease and received Investigational New Drug clearance for the HORIZON Phase 2 study of TNX-102 SL for major depressive disorder. Development progressed across the company's immunology and rare disease programs, including TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. Tonix is also advancing TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
The TONMYA launch represents a significant development for the estimated 6-12 million Americans living with fibromyalgia, a chronic condition characterized by widespread pain, fatigue, and cognitive difficulties. As the first new treatment option approved in over 15 years, TONMYA provides healthcare providers with an additional therapeutic approach for managing this complex condition. The early adoption by more than 1,500 healthcare providers suggests strong clinical interest in this new treatment modality.
Tonix's commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace SymTouch and Tosymra. The company is maximizing the science behind TONMYA in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder, potentially expanding the therapeutic applications of this medication beyond fibromyalgia.
For investors and industry observers, Tonix's progress demonstrates the company's transition to a commercial-stage biotechnology company with a marketed product generating revenue. The combination of commercial execution with TONMYA and continued pipeline advancement positions Tonix for potential growth across multiple therapeutic areas. The company's product development candidates remain investigational new drugs or biologics, and their efficacy and safety have not been established for any indication beyond TONMYA's approved use for fibromyalgia.
Additional information about Tonix Pharmaceuticals is available through the company's newsroom at https://ibn.fm/TNXP. The original press release containing these financial results and business updates can be viewed at https://ibn.fm/U3juw.
